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Abstract
Objectives: To assess the safety and feasibility and discuss the oncological impact of a portal vein
resection using the no-touch technique with a hepatectomy for locally advanced hilar cholangiocarcinoma.
Patients and Methods: From 2005 to March 2009, 49 patients with hilar cholangiocarcinoma under-
went a major right-sided hepatectomy with curative intent. Portal vein resection was performed using the
no-touch technique in 36 patients (PVR group) but the portal vein was not resected in the other 13
patients (NR group). Peri-operative data and histological findings were compared between the two
groups. Moreover, tumour recurrence and survival rates after surgery were calculated and compared for
each group.
Results: Although the tumours of the patients in the PVR group were more locally advanced, the residual
tumour status and tumour recurrence rate were similar and there was no significant difference in
long-term survival between the two groups: 5-year survival rates in the PVR and NR groups were 59% and
51%, respectively (P = 0.353). In-hospital mortality was encountered in 2 of the 49 patients.
Conclusion: A portal vein resection using the no-touch technique with a right-sided hepatectomy had
a positive impact on survival and is feasible in terms of long-term outcomes with acceptable mortality.
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Introduction
Vascular invasion has been the main cause of the irresectability of
hilar cholangiocarcinoma, making surgery for advanced hilar
cholangiocarcinoma challenging for biliary surgeons. However,
advances in surgical techniques during the last several decades
have made it possible to resect and reconstruct an involved portal
vein with acceptable morbidity and mortality.1–5
In general, resection of the portal vein is carried out when the
portal vein is adherent to the tumour and cannot be freed.
Although the curative resection rate has been increased owing to
en bloc resection of the portal vein, overall survival remains worse
in patients who have undergone a portal vein resection than in
those who have not.2,3 The procedure may disseminate the cancer
cells in the vicinity of the main tumour and worsen the prognoses
of patients undergoing a portal vein resection.2,3 To avoid dissemi-
nation, the portal vein is routinely resected and reconstructed
without any attempts to dissect it when the tumour abuts the
portal vein on pre-operative imaging. The surgical outcomes and
short-term survival of an aggressive resection, including simulta-
neous portal vein resection for hilar cholangiocarcinoma, have
been reported previously.1,6,7
However, the impact on survival of a portal vein resection using
the no-touch technique with a hepatectomy for hilar cholangiocar-
cinoma is unclear. The aim of this study was to assess the safety and
feasibility and discuss herein the oncological impact of a hepatec-
tomy combined with a no-touch resection of hilar malignancies.
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Patients and methods
From 2005 to 2009, 49 patients with hilar cholangiocarcinoma
underwent a major right-sided hepatectomy (hemihepatectomy
or trisectionectomy) and biliary reconstruction with curative
intent.
A left-sided hepatectomy for hilar cholangiocarcinoma pre-
dominantly involving the left hepatic duct has an anatomic dis-
advantage in terms of curability and is associated with a
significantly worse survival than that in a right hepatectomy.6
Hence, the patients who underwent a left-sided hepatectomy were
excluded from the present study.
The future remnant liver volume was routinely evaluated by
volumetric analysis and portal vein embolization was performed
prior to surgery if necessary.
Pre-operative biliary decompression was performed to reduce
the serum bilirubin concentration below 2 mg/dl for all patients
with jaundice and to control segmental cholangitis. Single or
double endoscopic naso-biliary drainage (ENBD) of the future
remnant liver was performed as an initial drainage. Second ENBD
catheters were placed to drain biliary trees in the future remnant
liver that were not decompressed by the first catheter, or to control
cholangitis. Alternatively, percutaneous transhepatic biliary
drainage (PTBD) was employed when drainage by ENBD was not
effective or a third catheter was required. The details of their
strategy have been reported previously.7
The decision to perform a portal vein resection was made based
on pre-operative imaging. When the tumour abutted the portal
vein on pre-operative imaging, the portal bifurcation was routinely
resected and reconstructed before the hepatic resection without an
attempt being made to dissect the portal vein. Portal vein recon-
struction was performed in an end-to-end fashion, taking care to
avoid torsion and stricturing of the anastomosis. The anastomosis
was created with a continuous 5/0 non-absorbable suture, using
the intra-luminal suturing technique for the posterior wall and the
over-and-over method for the anterior wall. At the end of the
operation, portal flow was confirmed by colour Doppler ultra-
sonography. The details of the procedure for portal vein resection
and reconstruction have been described previously.1,6
In the present study, all the hepatectomy procedures performed
included caudate lobectomy, extrahepatic bile duct resection, and
dissection of lymph nodes in the hepatoduodenal ligament and
around the pancreatic head. Biliary tract reconstruction was
achieved by a bilio-enterostomy using a Roux-en-Y jejunal limb,
and external biliary stents were placed through every anastomosis.
A pancreatoduodenectomy was performed for the patients with
evidence of an invasive lesion in the intrapancreatic bile duct,
based on the results of the pre-operative examination or intra-
operative frozen section analysis. Reconstruction during the
pancreatoduodenectomy was performed with an end-to-side pan-
creaticojejunostomy using a Child’s procedure.
Histological findings were evaluated using the TNM Classifica-
tion of Malignant Tumors by the International Union Against
Cancer (7th edition).8 The R0 was defined as the pathologically
tumour free status at the radial margin, hepatic and duodenal
margin of the resected bile duct and cut surface of the liver.
The peri-operative variables and clinicopathological data from
the groups were compared with the Mann-Whitney U-test, c2 test
or Fisher’s exact test.
Operative morbidity was defined as all the post-operative com-
plications that lengthened the hospital stay. In-hospital mortality
was defined as death within the same hospital admission. Ninety-
day mortality was defined as death after discharge from hospital
within 90 days.
Patients were followed regularly every 3 months via the outpa-
tient department. Serum levels of carcinoembryonic antigen and
carbohydrate antigen 19-9 were monitored every 3 months. An
abdominal computed tomography scan, and/or abdominal ultra-
sound or magnetic resonance imaging were performed every
6 months.
When suspicious new lesions emerged and showed progression
over several radiological examinations, a diagnosis of recurrence
was made. Elevation of tumour markers was adjunctive findings
for diagnosis of recurrence.
Post-operative survival rates, including any deaths, and
recurrence-free survival rates were calculated using the Kaplan–
Meier method. Differences in survival curves were compared
using the log-rank test. The results were considered statistically
significant when P < 0.05. The statistical software StatFlex ver.6
(Artech Co. Ltd, Osaka, Japan) was used for data analysis.
Results
Patient characteristics and surgical outcomes
In 13 of the 49 patients, no resection was performed for the portal
bifurcation because the tumour was located distant from the
portal vein (NR group). In the remaining 36 patients, a portal vein
resection and reconstruction using the no-touch technique (PVR
group) was performed. The patients’ characteristics and peri-
operative variables are shown in Table 1. The peri-operative data
from the patients in the PVR group were similar to those in the
NR group. Post-operative complications prolonging the hospital
stay are presented in Table 2. There were no post-operative com-
plications directly related to PVR and reconstruction.
One patient in PVR group died as a result of abdominal bleed-
ing owing to the rupture of a pseudoaneurysm of the proper
hepatic artery and one patient in NR group died of liver failure
during hospital stay. Two patients in the NR group died after
discharge from the hospital within 90 days of surgery. One of these
two patients died of carcinomatous lymphangiomatosis of hilar
cholangiocarcinoma and another died of other disease (detail
unknown).
Histological findings and post-operative survival
Histological data are shown in Table 3. All the patients in the NR
group had a negative radial margin at the hilar bile duct. The
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tumour recurrence rate were similar between the two groups
(P = 0.508).
Six out of 13 patients in the NR group and 12 out of 36 patients
in the PVR group developed tumour recurrence.
Six patients in the NR group developed tumour recurrence at a
distant site (liver metastasis, lung metastasis, mediastinal lymph
node metastasis and carcinomatous lymphangiomatosis) as com-
pared with seven patients in the PVR group (liver metastasis and
lung metastasis) (P = 0.128). None of patients in the NR group
developed locoregional recurrence or peritoneal dissemination in
comparison with five patients in the PVR group (P = 0.128).
There was no significant difference in long-term survival
between the two groups (P = 0.353) (Fig. 1). The recurrence-free
survival also did not differ between the two groups (P = 0.072)
(Fig. 2).
Discussion
Portal vein invasion is still a major obstacle to resection of
advanced hilar cholangiocarcinoma. However, a recent develop-
ment in surgical techniques has increased the rate of resectability
of hilar cholangiocarcinoma.2 Although the curative resection rate
has increased owing to en bloc resection of the portal vein, overall
survival remains worse in patients who have undergone portal
vein resection than in those who have not.3,9–11 Moreover, even in
patients with negative histological margins, local or peritoneal
Table 1 Comparison of characteristics and peri-operative variables of the patients in NR and PVR group
NR (n = 13) PVR (n = 36) P-value
Age (years)a 68 (58–77) 68.5 (56–78) 0.768
Gender (male/female) 10/3 25/11 0.731
Pre-operative bilirubin level (mg/dl)a 0.8 (0.2–1.0) 0.8 (0.4–1.5) 0.735
Pre-operative cholangitis present 2 8 0.710
Biliary access (PTBD/endoscopy/none) 2/9/2 11/23/2 0.368
ICG-R15a 10.6 (2.9–20.0) 11.2 (4.2–18.4) 0.745
Pancreatoduodenectomy performed 8 8 0.016
Operating time (min)a 623 (479–902) 653 (444–979) 0.564
Blood loss (ml)a 1610 (860–3840) 1902 (861–6010) 0.105
Post-operative liver failure 2 3 0.598
Post-operative hospital stay (days) 32 (18–88) 35.5 (17–146) 0.973
In-hospital mortality 1 1 0.464
Tumour recurrence 6 12 0.508
aValues are medians (ranges).
ICG-R15, indocyanine green retention rate at 15 min; NR, patients without a portal vein resection; PVR, patients who underwent a portal vein resection
using the no-touch technique.
Table 2 Morbidity and mortality in patients undergoing a hepatectomy with and without a portal vein resection
NR (n = 13) PVR (n = 36) Total (n = 49)
No. of patients with morbidity 10 21 31
Frequency of events
Wound infection 1 4 5
Intra-abdominal bleeding 3 2 5
Liver failure 2 2 4
Bile leakage 0 2 2
Intra-abdominal abscess 3 2 5
Pancreatic fistula 4 7 11
Pancreatojejunostomy insufficiency 1 0 1
Interstitial pneumonia 0 1 1
Outflow disturbance of hepatic vein 0 1 1
No. of patients with in hospital mortality 1 1 2
No. of patients with 90-day mortality 2 0 2
NR, patients without a portal vein resection; PVR, patients who underwent a portal vein resection using the no-touch technique.
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recurrence can occur during the follow-up period as shown in this
study.
Kobayashi et al.12 reported that after a curative resection, recur-
rences occurred at locoregional or peritoneal sites in 19 of
42 patients. In concurrence with those findings, Jarnagin et al.4
indicated that 65% of all recurrences, including a locoregional
recurrence, along the resection margin probably arose from
microscopic residual disease. Most hilar malignancies have
microscopic perineural tumour infiltration.3,9,12,13 In fact, in the
current series, 41 patients had histological perineural invasion.
Thus, recurrence is possibly related to the microscopic dissemi-
nation of cancer cells during dissection of the portal vein from
the tumour when the involved bile duct lies very close to the
portal vein. To avoid microscopic dissemination of cancer cells,
the decision to perform a portal vein resection should be made
based on pre-operative image findings and the portal bifurcation
is resected without an attempt to dissect it from the hilar bile
duct. The prognosis and recurrence-free survival of the patients
in the PVR group was not significantly different from the prog-
nosis and recurrence-free survival of those in the NR group
(Figs 1, 2). Some authors recently reported the oncological supe-
riority or non-inferiority of a portal vein resection with a hepa-
tectomy to a conventional major hepatectomy.5,13 Neuhaus et al.13
reported that the prognosis of patients who underwent a hilar en
bloc resection using the no-touch technique was significantly
superior to the prognosis of patients who underwent a major
hepatectomy alone. However, in their series, the frequency of
microscopic vascular invasion was similar between both (with
and without portal vein resection) groups and the decision to
perform a portal vein resection was made intra-operatively.
Therefore, it is possible for patients who require a portal vein
resection to undergo a hepatectomy alone but with a potentially
relatively poor prognosis. Meanwhile, owing to the preoperative
decision to perform portal vein resection, none of the patients in
the NR group had microscopic portal vein invasion and all the
patients in the NR group had a negative radial margin at the hilar
bile duct.
Although, in the present series, microscopic portal invasion was
significantly more frequent and the T stage was significantly more
advanced in the patients in the PVR group than in those in the NR
Table 3 Comparison of histological findings of the patients in NR and PVR group
NR (n = 13) PVR (n = 36) P-value
Tumour extention (pT1/2a/2b/3/4)a 0/12/1/0/0 4/18/1/3/10 0.049
Nodal status (N0/N1)a 8/5 24/12 0.667
UICC Stage (I/II/IIIA/IIIB/IVA)a 0/8/2/3/0 4/12/4/6/10 0.122
Residual tumour status (R0/R1)a 12/1 28/8 0.412
Microscopic portal vein invasion (-/+) 13/0 25/11 0.047
Microscopic perineural infiltration (-/+) 3/10 5/31 0.663
aTNM Classification of Malignant Tumors (UICC, 7th edn).
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Figure 1 The 1-, 3- and 5-year survival rates were respectively 80%, 66% and 59% (median survival, 20.5 months) in the patients who
underwent a portal vein resection using the no-touch technique (PVR) group and 69%, 51%, and 51% (median survival, 20.5 months) in the
patients without a portal vein resection (NR) group
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group, the residual tumour status and tumour recurrence rate
were similar between the groups.
Locoregional recurrence or peritoneal dissemination had
occurred in five patients in the PVR group. By contrast, none in
the NR group had developed locoregional recurrence or perito-
neal dissemination. Locoregional recurrence or peritoneal dis-
semination might have been unlikely to occur because the tumour
was located distant from the portal vein in all patients in the NR
group. It seems to be difficult to completely prevent recurrence of
locally advanced hilar cholangiocarcinoma even if a R0 resection
is performed using the no-touch technique. One of the reasons for
this may be peritoneal recurrence associated with PTBD. Actually
one patient who developed peritoneal recurrence underwent
PTBD before surgery; however, there was no difference in pre-
operative biliary drainage between the NR group and the PVR
group (P = 0.368). Locoregional recurrence or peritoneal dissemi-
nation were less frequent compared with other reports12 and
therefore this procedure may reduce the chance of locoregional
recurrence or peritoneal dissemination.
Therefore, pre-operative determination to perform concomi-
tant portal vein resection and en bloc hilar resection using the
no-touch technique can provide a good chance for prolonged
survival of patients with advanced hilar cholangiocarcinoma,
especially locally advanced disease.
The reported morbidity and mortality in patients who under-
went a hepatectomy with portal vein resection were 30.0–
54.0%5,9,11 and 2.0–12.4%, respectively.5,9,11,13,14 In the present
study, the morbidity rate was relatively high, but there were no
complications directly related to portal vein resection and recon-
struction. The current mortality rate was within previous
reported limits. In addition, the risk of post-operative liver failure
and in-hospital mortality were not significantly different between
the PVR and NR groups. Therefore, possible survival benefits of
the no-touch resection of the portal vein appear to compensate for
an increased risk associated with surgery, particularly when the
lack of alternative curative approaches is considered.
A limitation of this study is the small number of patients in the
population and a further prospective randomized study should be
performed.
In conclusion, in spite of the relatively high morbidity, aggres-
sive resection for hilar cholangiocarcinoma, when performed in
accordance with strict management strategy, achieved acceptably
low mortality. The no-touch resection of the portal bifurcation in
a right hepatectomy for locally advanced hilar cholangiocarci-
noma enables equivalent surgical outcomes to be obtained as seen
in those patients without portal vein invasion. This procedure for
locally advanced disease has a positive impact on survival and is
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Figure 2 The 1- and 3-year recurrence free survival rates were, respectively, 80% and 62% (median survival, 20.5 months) in the patients
who underwent a portal vein resection using the no-touch technique (PVR) group and 69% and 45% (median survival, 20.5 months) in the
patients without a portal vein resection (NR) group
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